As of November 6, 2026, Lyell Immunopharma, Inc. is a publicly traded company (Nasdaq: LYEL); its largest reported holder is ARCH Venture Fund IX, L.P., with 13.9% on Schedule 13G/A of May 15, 2026, then Innovative Cellular Therapeutics Holdings Limited (12.3%) (Schedule 13G/A, May 15, 2026).
Is this your company?
About to sign with, pay or invest in Lyell Immunopharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Lyell Immunopharma, Inc. a real, registered company?
- Lyell Immunopharma, Inc. files with the SEC under CIK 1806952 (its SEC filings).
- Its shares are listed under the ticker LYEL on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Lyell Immunopharma, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Innovative Cellular Therapeutics Holdings Limited (filed 2026-06-18).
Who are Lyell Immunopharma, Inc.'s owners and officers?
Lyell Immunopharma, Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | James B. Tananbaum | 2.7% |
| Schedule 13G/A, 2026-06-18 | Innovative Cellular Therapeutics Holdings Limited | 12.3% |
| Schedule 13G/A, 2026-05-15 | Arch Venture Fund Ix, L.P. | 13.9% |
| Schedule 13G/A, 2026-05-11 | Mwg Caph LTD | 4.3% |
| Schedule 13G/A, 2026-05-08 | Explore Investments LLC | 6.6% |
| Schedule 13G, 2026-04-21 | Euler Fund, L.P. | 6.71% |
| Schedule 13G/A, 2025-11-14 | Arch Venture Fund Ix, L.P. | 13% |
| Schedule 13G/A, 2025-11-14 | James B. Tananbaum | 7.6% |
| Schedule 13G, 2025-11-13 | Innovative Cellular Therapeutics Holdings LTD | 9.8% |
| Schedule 13G/A, 2025-11-12 | Newton (Ptc) Limited | 3.93% |
| Schedule 13G, 2025-08-19 | Explore Investments LLC | 5.4% |
| Schedule 13G, 2025-08-01 | Gates Frontier, LLC | 5.6% |
Questions about who owns Lyell Immunopharma, Inc.
Who owns Lyell Immunopharma, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Lyell Immunopharma, Inc.: Arch Venture Fund Ix, L.P. (13.9%, Schedule 13G/A, filed 2026-05-15), Innovative Cellular Therapeutics Holdings Limited (12.3%, Schedule 13G/A, filed 2026-06-18), Innovative Cellular Therapeutics Holdings LTD (9.8%, Schedule 13G, filed 2025-11-13), Euler Fund, L.P. (6.71%, Schedule 13G, filed 2026-04-21) and Explore Investments LLC (6.6%, Schedule 13G/A, filed 2026-05-08); 1 more is listed above.
Who are the largest shareholders of Lyell Immunopharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Lyell Immunopharma, Inc. on this page are Arch Venture Fund Ix, L.P. (13.9%), Innovative Cellular Therapeutics Holdings Limited (12.3%) and Innovative Cellular Therapeutics Holdings LTD (9.8%).
When did Arch Venture Fund Ix, L.P. buy into Lyell Immunopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Arch Venture Fund Ix, L.P. on this page is the Schedule 13G/A, filed 2025-11-14, reporting 13%; its latest, Schedule 13G/A filed 2026-05-15, reports 13.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Lyell Immunopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lyell Immunopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lyell Immunopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Lyell Immunopharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- ARCH Venture Fund IX, L.P., a 10% owner: 3,747,790 shares (15.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-05).
- ARCH Venture Partners IX, L.P., a 10% owner: 3,747,790 shares (15.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-05).
- ARCH Venture Partners IX, LLC, a 10% owner: 3,747,790 shares (15.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-05).
- ARCH Venture Partners XIII, L.P., a 10% owner: 3,747,790 shares (15.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-05).
- ARCH Venture Fund IX Overage, L.P., a 10% owner: 3,747,790 shares (15.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-05).
Shares outstanding: 24,585,565 as of 2026-10-30, from the company's latest SEC cover page.
How much has Lyell Immunopharma, Inc. raised?
No fundraising or offering filing from Lyell Immunopharma, Inc. is on file with us.
Keep reading
More on Lyell Immunopharma, Inc. and the records around it.
Lyell Immunopharma, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Gates Frontier, LLC also filed stake reports on 1 other company: Evolv Technologies Holdings, Inc. (Sep 2025)
- Newton (PTC) Limited also filed stake reports on 1 other company: Figure Technology Solutions, Inc. (Nov 2025)
- ARCH Venture Fund IX, L.P. also filed stake reports on 2 other companies: Vir Biotechnology, Inc. (Nov 2026), Sana Biotechnology, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/lyell-immunopharma